ReShape Lifesciences Files 8-K on Financials

TL;DR

ReShape Lifesciences dropped an 8-K on May 15th detailing their financial condition. Check it out.

AI Summary

ReShape Lifesciences Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 18 Technology Dr, Suite 110, Irvine, California.

Why It Matters

This 8-K filing provides an update on ReShape Lifesciences' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• ReShape Lifesciences Inc. (company) — Registrant
• May 15, 2024 (date) — Date of earliest event reported
• 18 Technology Dr, Suite 110, Irvine, California 92618 (location) — Address of principal executive offices
• Obalon Therapeutics Inc (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — nge on which Registered Common stock, $0.001 par value per share RSLS The Nasdaq

Filing Documents

• rsls-20240515x8k.htm (8-K) — 34KB
• rsls-20240515xex99d1.htm (EX-99.1) — 185KB
• rsls-20240515xex99d1001.jpg (GRAPHIC) — 4KB
• 0001558370-24-008491.txt ( ) — 359KB
• rsls-20240515.xsd (EX-101.SCH) — 4KB
• rsls-20240515_def.xml (EX-101.DEF) — 3KB
• rsls-20240515_lab.xml (EX-101.LAB) — 16KB
• rsls-20240515_pre.xml (EX-101.PRE) — 10KB
• rsls-20240515x8k_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On May 15, 2024, ReShape Lifesciences Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference The information furnished herewith pursuant to Item 2.02 of this Current Report and in Exhibit 99.1 hereto is being "furnished" in accordance with General Instruction B.2 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated May 15, 2024 104 Cover Page Interactive Data File (embedded with inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Tom Stankovich Tom Stankovich Chief Financial Officer Dated: May 20, 2024

View Full Filing

View this 8-K filing on SEC EDGAR